What does Nexien BioPharma, Inc. do?

Nexien BioPharma, Inc. (NXEN) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is NXEN's market cap?

Nexien BioPharma, Inc. (NXEN) has a market capitalization of approximately $7,077, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does NXEN pay a dividend?

No — Nexien BioPharma, Inc. (NXEN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Nexien BioPharma, Inc. (NXEN) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

NXEN

Nexien BioPharma, Inc.

OTC·Drug Manufacturers, Specialty & Generic · Healthcare

$0.00$0.00+0.00%

Market cap$7.08K·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−99.87%CAGR −73.74%

Select date range

FromTo

Nov 29, 2017Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

NXEN does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateMay 12

Last Report DateMay 14

Reported vs Estimate−$0.00

Earnings Surprise—

FinancialsFinancials Tab

Revenue$0.00

Net Income−$188.08K

Net Margin—

Operating Cash Flow−$61.78K

Capital Expenditures$1.00

Free Cash Flow−$61.78K

Return on Equity—

Return on Invested Capital19.0%

Net Debt$367.09K

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for NXEN and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how NXEN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NXEN and 80,000+ other tickers.

About Nexien BioPharma, Inc.

Nexien BioPharma, Inc., a pharmaceutical firm headquartered in Glendale, Colorado, concentrates its efforts on the research, advancement, and market introduction of cannabinoid-derived medications. The company utilizes both pre-clinical and clinical development paths to address a variety of diseases, medical conditions, and disorders. It adopted its current name in September 2018, having previously operated as Intiva BioPharma Inc.

CEO: Richard S. Greenberg
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: OTC
Employees: 10
Website: www.nexienbiopharma.com

Peers

Neptune Wellness Solutions Inc.

Cap

$453.0

DVLP

Golden Developing Solutions, Inc.

Cap

$14.1K

Latest News

News Tab

No recent news available.

Frequently Asked Questions About NXEN

What does Nexien BioPharma, Inc. do?: Nexien BioPharma, Inc. (NXEN) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is NXEN's market cap?: Nexien BioPharma, Inc. (NXEN) has a market capitalization of approximately $7,077, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does NXEN pay a dividend?: No — Nexien BioPharma, Inc. (NXEN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is NXEN profitable?: Nexien BioPharma, Inc. (NXEN) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.